What’s Changing
- Manufacturing incentives
- Procurement preferences
- Increased scrutiny or trade requirements
- Localized supply chain support
Why It Matters
- Cost and margin pressure on imported APIs/drugs
- Regulatory alignment and proximity
- Shifting supply chain expectations
What Companies Should Do Now
- Evaluate U.S. contract manufacturing partnerships
- Explore small-scale facility options or joint ventures
- Prepare regulatory documents for U.S. tech transfer
- Segment supply chains for U.S. market delivery
Executive Recommendation
As global pharmaceutical policies shift toward domestic resiliency, organizations with proactive regulatory alignment, diversified supply chains, and U.S. based partnerships will be better positioned for long-term success. Companies that prepare now can mitigate disruption, maintain market access, and strengthen their operational resilience.
Final Thought
Are you preparing for U.S. market expansion, responding to regulatory shifts, or navigating pharmaceutical supply chain complexities? Let’s Talk.
